2021 BCMA-Directed Therapies in Multiple Myeloma
2021 BCMA Directed Therapies in Multiple Myeloma, is a CME-accredited, half-day conference featuring leading experts in multiple myeloma who will provide a comprehensive overview of current state and the future implications of B-cell Maturation Antigen (BCMA) directed therapies in multiple myeloma (MM). The goal of this activity is to improve the knowledge and the competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with MM. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in MM focusing on multiple immunotherapeutic options with BCMA as the lead target. Expert faculty will utilize didactics, case-based presentations, and related panel discussions on several current and emerging BCMA directed therapies including bispecific antibodies, CART and ADC available for MM patients, and how to sequence them in an effective manner to provide the best outcomes. The Binaytara Foundation will utilize a virtual format that includes both online recorded materials and live web-based interactive discussions to provide an easily accessible environment for learning, engagement, and dialogue with peers and presenters.
- Cancer care professionals
- Practicing hematologists and oncologists
- Oncology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
Upon successful completion of this educational activity, participants will be able to:
- Review the mechanism of resistance and determinants of response to BCMA directed therapies
- Describe the role, including efficacy and adverse events, of BCMA-directed CAR-T therapy in MM
- Outline the role, including efficacy and adverse events, of BMCA directed BsB and ADC in MM.
- Integrate BCMA directed therapies in the management of relapsed and/or refractory MM
- Identify and manage adverse events from BCMA directed therapies
Conference Chair: Binod Dhakal, MD
All times below are listed in Pacific Standard Time
|7:15AM - 8:00AM||Registration/Networking|
|8:00AM - 8:30AM||BCMA CAR-T in MM: Current state and future implications|
|8:30AM - 9:00AM||Role of BCMA bispecific antibodies in MM|
|9:00AM - 9:30AM||BREAK|
|9:30AM - 10:00AM||Optimal sequencing of CAR-T vs. bispecific antibodies and other immune therapies in MM|
|10:00AM - 10:30AM||Understanding the determinants of response and mechanism of resistance to BCMA targeted agents|
|10:30AM - 11:00AM||Case-based discussion|
- 2.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 2.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.50 Contact Hours.
- 0.00 Participation